anti-inflammatoty and immuno-therapy - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.83 [0.67, 1.03]< 124%28 studies (28/-)95.5 %some concerncritical moderatecrucial-
death or transfer to ICU 0.65 [0.35, 1.22]< 10%1 study (1/-)90.9 %NAnot evaluable crucial-
deaths 0.78 [0.67, 0.90]< 132%50 studies (50/-)100.0 %some concerncritical moderatecrucial-
deaths (time to event analysis only) 0.86 [0.63, 1.18]< 157%10 studies (10/-)82.5 %some concernlow moderatecrucial-
clinical deterioration 0.63 [0.45, 0.88]< 10%4 studies (4/-)99.6 %some concernnot evaluable moderateimportant-
clinical improvement 1.33 [1.13, 1.57]> 159%21 studies (21/-)100.0 %some concerncritical moderateimportant-
clinical improvement (14-day) 1.42 [1.05, 1.92]> 156%7 studies (7/-)98.8 %some concernserious moderateimportant-
clinical improvement (28-day) 1.32 [0.98, 1.77]> 133%9 studies (9/-)96.8 %some concernserious moderateimportant-
clinical improvement (7-day) 2.47 [0.37, 16.27]> 172%2 studies (2/-)82.5 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.14 [0.99, 1.31]> 133%10 studies (10/-)96.1 %some concerncritical moderateimportant-
death or ventilation 1.07 [0.74, 1.56]< 147%6 studies (6/-)35.6 %some concernnot evaluable moderateimportant-
hospital discharge 1.20 [0.90, 1.60]> 135%5 studies (5/-)89.7 %lowserious highimportant-
mechanical ventilation 0.86 [0.66, 1.13]< 10%15 studies (15/-)85.5 %some concernlow moderateimportant-
mechanical ventilation (time to event analysis only) 0.66 [0.25, 1.72]< 10%1 study (1/-)80.2 %NAnot evaluable important-
radiologic improvement (14-day) 3.53 [1.19, 10.46]> 10%2 studies (2/-)98.9 %some concernnot evaluable moderateimportant-
viral clearance 6.97 [0.23, 210.35]> 189%2 studies (2/-)86.4 %some concernnot evaluable moderateimportant-
viral clearance by day 14 7.68 [0.34, 173.70]> 190%2 studies (2/-)89.7 %some concernnot evaluable moderateimportant-
ICU admission 0.62 [0.44, 0.86]< 10%8 studies (8/-)99.8 %some concernnot evaluable moderatenon important-
off oxygenation 1.65 [0.05, 50.02]> 181%2 studies (2/-)61.1 %highnot evaluable lownon important-
recovery 1.30 [0.64, 2.66]> 19%2 studies (2/-)76.5 %lownot evaluable highnon important-

safety endpoints 00

related AE (TRAE) 1.26 [0.14, 11.07]< 10%2 studies (2/-)41.9 %some concernnot evaluable moderateimportant-
serious adverse events 1.08 [0.89, 1.32]< 123%16 studies (16/-)21.9 %some concernlow moderateimportant-
superinfection 0.91 [0.32, 2.60]< 160%3 studies (3/-)56.9 %some concernnot evaluable moderateimportant-
adverse events 1.12 [0.96, 1.31]< 10%11 studies (11/-)7.8 %some concernlow moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.